Research programme: therapeutics for uro-oncologic disorders - Astellas Pharma/CUOG/CUA

Drug Profile

Research programme: therapeutics for uro-oncologic disorders - Astellas Pharma/CUOG/CUA

Latest Information Update: 18 Feb 2014

Price : $50

At a glance

  • Originator Canadian Urological Association; Canadian Urological Oncology Group
  • Developer Astellas Pharma Canada; Canadian Urological Association; Canadian Urological Oncology Group
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Prostate cancer

Most Recent Events

  • 12 Feb 2014 Early research in Prostate cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top